Vitamin D growth inhibition of breast cancer cells: Gene expression patterns assessed by cDNA microarray

Breast Cancer Research and Treatment

Volumn 80, Issue 1, 2003, Pages 49-62

  Swami, Srilatha ^a   Raghavachari, Nalini ^b   Muller, Uwe R ^b   Bao, Yijia P ^b   Feldman, David ^a,c  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Corning Inc ^*  (United States)

^c STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

1,25(OH)2D3; cDNA microarray; Estrogen receptor; Gene expression; MCF 7; MDA MB 231

Indexed keywords

CALCITRIOL; CASPASE; CELL ADHESION MOLECULE; COMPLEMENTARY DNA; CYCLINE; CYTOKINE; ESTROGEN RECEPTOR ALPHA; GROWTH FACTOR; MATRIX METALLOPROTEINASE; PHOSPHOTRANSFERASE; PROTEIN P130; PROTEIN P21; PROTEIN P53; SOMATOMEDIN BINDING PROTEIN 5; STEROID RECEPTOR; TRANSCRIPTION FACTOR; TRANSFORMING GROWTH FACTOR BETA2; VITAMIN D;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CELL CYCLE; CELL GROWTH; CELL STRAIN MCF 7; CONTROLLED STUDY; DNA MICROARRAY; GENE EXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN CELL; METABOLITE; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; UNINDEXED SEQUENCE;

ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; CALCITRIOL; DNA, NEOPLASM; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMERASE CHAIN REACTION; TUMOR CELLS, CULTURED; UP-REGULATION;

EID: 0037485699     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1024487118457     Document Type: Article

References (59)

1. Mangelsdorf D, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P, Evans R: The nuclear receptor superfamily: the second decade. Cell 83: 835-839, 1995
2. Tsai MJ, O'Malley BW: Molecular mechanisms of action of steroid/thyroid receptor super family members. Annu Rev Biochem 63: 451-486, 1994
3. Osborne CK: Steroid hormone receptors in breast cancer management. Breast Cancer Res Treat 51: 227-238, 1998
4. Feldman D, Malloy PJ, Gross C: Vitamin D: Biology, Action and clinical implications. In: Marcus R, Feldman D, Kelsey J (eds) Osteoporosis. Academic Press, New York, 2001, pp 257-303
5. Colston KW, Hansen C: Mechanisms implicated in the growth regulatory effects of vitamin D in breast cancer. Endocr Relat Cancer 9: 45-59, 2002
6. 3, inhibits the growth of human breast cancer in vitro and in vivo without causing hypercalcemia. Endocrinology 129: 832-837, 1991
7. 3 analogs in breast cancer cells. Cancer Res 56: 2789-2794, 1996
8. Colston KW, Perks CM, Xie SP, Holly JM: Growth inhibition of both MCF-7 and Hs578T human breast cancer cell lines by vitamin D analogues is associated with increased expression of insulin-like growth factor binding protein-3. J Mol Endocrinol 20: 157-162, 1998
9. Xie SP, Pirianov G, Colston KW: Vitamin D analogues suppress IGF-I signalling and promote apoptosis in breast cancer cells. Eur J Cancer 35: 1717-1723, 1999
10. 3 and EB1089 on cell cycle kinetics and apoptosis in MCF-7 breast cancer cells. Breast Cancer Res Treat 42: 31-41, 1997
11. 3 and its analogues on induction of apoptosis in breast cancer cells. J Steroid Biochem Mol Biol 58: 395-401, 1996
12. Hansen C, Rohde L, Madsen MW, Hansen D, Colston KW, Pirianov G, Holm PK, Binderup L: MCF-7/VD(R): a new vitamin D resistant cell line. J Cell Biochem 82: 422-436, 2001
13. Narvaez CJ, Welsh J: Role of mitochondria and caspases in vitamin D-mediated apoptosis of MCF-7 breast cancer cells. J Biol Chem 276: 9101-9107, 2001
14. James SY, Mackey AG, Binderup L, Colston KW: Effects of a new synthetic vitamin D analogue, EB1089, on the oestrogen-responsive growth of human breast cancer cells. J Endocrinol 141: 555-563, 1994
15. Stoica A, Saceda M, Fakhro A, Solomon HB, Fenster BD, Martin MB: Regulation of estrogen receptor-alpha gene expression by 1,25-dihydroxyvitamin D in MCF-7 cells. J Cell Biochem 75: 640-651, 1999
16. 3 down-regulates estrogen receptor abundance and suppresses estrogen actions in MCF-7 human breast cancer cells. Clin Cancer Res 6: 3371-3379, 2000
17. 3 analogues: a novel class of potent inhibitors of proliferation and inducers of differentiation of human breast cancer cell lines. Cancer Res 55: 2822-2830, 1995
18. Wang Q, Lee D, Sysounthone V, Chandraratna RAS, Christakos S, Korah R, Wieder R: 1,25-dihydroxyvitamin D3 and retonic acid analogues induce differentiation in breast cancer cells with function- and cell-specific additive effects. Breast Cancer Res Treat 67: 157-168, 2001
19. Raghavachari N, Bao YP, Li G, Xie X, Muller UR: Reduction of auto-fluorescence on DNA microarrays and slide surfaces by treatment with sodium borohydride. Anal Biochem 312: 101-105, 2003
20. Bao P, Frutos AG, Greef C, Lahiri J, Muller U, Peterson TC, Warden L, Xie X: High-sensitivity detection of DNA hybridization on microarrays using resonance light scattering. Anal Chem 74: 1792-1797, 2002
21. Bieche I, Parfait B, Tozlu S, Lidereau R, Vidaud M: Quantitation of androgen receptor gene expression in sporadic breast tumors by real-time RT-PCR: evidence that MYC is an AR-regulated gene. Carcinogenesis 22: 1521-1526, 2001
22. Narvaez CJ, Zinser G, Welsh J: Functions of 1alpha,25-dihydroxyvitamin D(3) in mammary gland: from normal development to breast cancer. Steroids 66: 301-308, 2001
23. 3 in T47D human breast cancer cells. J. Steroid Biochem Mol Biol 54: 147-153, 1995
24. Hall JM, McDonnell DP: The estrogen receptor beta-isoform (ERbeta) of the human estrogen receptor modulates ERalpha transcriptional activity and is a key regulator of the cellular response to estrogens and antiestrogens. Endocrinology 140: 5566-5578, 1999
25. Krishnan A, Feldman D: Regulation of vitamin D receptor abundance. In: Feldman D, Glorieux FH, Pike JW (eds) Vitamin D. Academic Press, San Diego, CA, 1997, pp 179-200
26. Gross C, Krishnan AV, Malloy PJ, Eccleshall TR, Zhao XY, Feldman D: The vitamin D receptor gene start codon polymorphism: a functional analysis of FokI variants. J Bone Miner Res 13: 1691-1699, 1998
27. 3 to inhibit growth of DU 145 human prostate cancer cells by blocking 24-hydroxylase activity. Endocrinology 140: 2071-2076, 1999
28. 3 on the cell cycle genes, cyclin D1, p21 and p27 in MCF-7 cells. Mol Cell Endocrinol 142: 57-65, 1998
29. 3 is linked to dephosphorylation of retinoblastoma gene product. Biochem Biophys Res Commun 196: 487-493, 1993
30. 3 and its analogs on growth control and tumorigenesis. Front Biosci 6: D820-D848, 2001
31. Jensen SS, Madsen MW, Lukas J, Binderup L, Bartek J: Inhibitory effects of 1alpha,25-dihydroxyvitamin D(3) on the G(1)-S phase-controlling machinery. Mol Endocrinol 15: 1370-1380, 2001
32. 3 inhibit the growth of human breast cancer cells in vitro and in vivo. Cancer Res 60: 2673-2679, 2000
33. Mathiasen IS, Lademann U, Jaattela M: Apoptosis induced by vitamin D compounds in breast cancer cells is inhibited by Bcl-2 but does not involve known caspases or p53. Cancer Res 59: 4848-4856, 1999
34. Thomas A, Giesler T, White E: p53 mediates bcl-2 phosphorylation and apoptosis via activation of the Cdc42/JNK1 pathway. Oncogene 19: 5259-5269, 2000
35. Bates S, Rowan S, Vousden KH: Characterisation of human cyclin G1 and G2: DNA damage inducible genes. Oncogene 13: 1103-1109, 1996
36. Okamoto K, Prives C: A role of cyclin G in the process of apoptosis. Oncogene 18: 4606-4615, 1999
37. Kimura SH, Ikawa M, Ito A, Okabe M, Nojima H: Cyclin G1 is involved in G2/M arrest in response to DNA damage and in growth control after damage recovery. Oncogene 20: 3290-3300, 2001
38. Chen L, Shinde U, Ortolan TG, Madura K: Ubiquitin-associated (UBA) domains in Rad23 bind ubiquitin and promote inhibition of multi-ubiquitin chain assembly. EMBO Rep 2: 933-938, 2001
39. Bertolaet BL, Clarke DJ, Wolff M, Watson MH, Henze M, Divita G, Reed SI: UBA domains of DNA damage-inducible proteins interact with ubiquitin. Nat Struct Biol 8: 417-422, 2001
40. Takahashi T, Caviness Jr VS: PCNA-binding to DNA at the G1/S transition in proliferating cells of the developing cerebral wall. J Neurocytol 22: 1096-1102, 1993
41. Paunesku T, Mittal S, Protic M, Oryhon J, Korolev SV, Joachimiak A, Woloschak GE: Proliferating cell nuclear antigen (PCNA): ringmaster of the genome. Int J Radiat Biol 77: 1007-1021, 2001
42. Zamparelli A, Masciullo V, Bovicelli A, Santini D, Ferrandina G, Minimo C, Terzano P, Costa S, Cinti C, Ceccarelli C, Mancuso S, Scambia G, Bovicelli L, Giordano A: Expression of cell-cycle-associated proteins pRB2/p130 and p27kip in vulvar squamous cell carcinomas. Hum Pathol 32: 4-9, 2001
43. 3 enhances the susceptibility of breast cancer cells to doxorubicin-induced oxidative damage. Cancer Res 59: 862-867, 1999
44. Koren R, Hadari-Naor I, Zuck E, Rotem C, Liberman UA, Ravid A: Vitamin D is a prooxidant in breast cancer cells. Cancer Res 61: 1439-1444, 2001
45. Lindner DJ, Hofmann ER, Karra S, Kalvakolanu DV: The interferon-beta and tamoxifen combination induces apoptosis using thioredoxin reductase. Biochim Biophys Acta 1496: 196-206, 2000
46. Rozen F, Yang XF, Huynh H, Pollak M: Antiproliferative action of vitamin D-related compounds and insulin-like growth factor-binding protein 5 accumulation. J Natl Cancer Inst 89: 652-656, 1997
47. Boyle BJ, Zhao XY, Cohen P, Feldman D: Insulin-like growth factor binding protein-3 mediates 1 alpha,25-dihydroxyvitamin d(3) growth inhibition in the LNCaP prostate cancer cell line through p21/WAF1. J Urol 165: 1319-1324, 2001
48. Zumkeller W: IGFs and IGFBPs: surrogate markers for diagnosis and surveillance of tumour growth? Mol Pathol 54: 285-288, 2001
49. Schmidt M, Lichtner RB: EGF receptor targeting in therapy-resistant human tumors. Drug Resist Updat 5: 11-18, 2002
50. Zhang W, Wang H, Song SW, Fuller GN: Insulin-like growth factor binding protein 2: gene expression microarrays and the hypothesis-generation paradigm. Brain Pathol 12: 87-94, 2002
51. 3 and its analogues. J Biol Chem 273: 7749-7756, 1998
52. Yang L, Yang J, Venkateswarlu S, Ko T, Brattain MG: Autocrine TGFbeta signaling mediates vitamin D3 analog-induced growth inhibition in breast cells. J Cell Physiol 188: 383-393, 2001
53. Hu X, Zuckerman KS: Transforming growth factor: signal transduction pathways, cell cycle mediation, and effects on hematopoiesis. J Hematother Stem Cell Res 10: 67-74, 2001
54. Miki Y, Swensen J, Shattuck-Eidens D, Futreal PA, Harshman K, Tavtigian S, Liu Q, Cochran C, Bennett LM, Ding W, et al.: A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. Science 266: 66-71, 1994
55. Wang SC, Lin SH, Su LK, Hung MC: Changes in BRCA2 expression during progression of the cell cycle. Biochem Biophys Res Commun 234: 247-251, 1997
56. MacDougall JR, Matrisian LM: Contributions of tumor and stromal matrix metalloproteinases to tumor progression, invasion and metastasis. Cancer Metastasis Rev 14: 351-362, 1995
57. 3 and its analogues down-regulate cell invasion-associated proteases in cultured malignant cells. Cell Growth Diff 11: 221-229, 2000
58. 3 and its analog EB1089 under growth-inhibitory conditions in squamous carcinoma Cells. Mol Endocrinol 15: 1127-1139, 2001
59. 3 analog EB1089 signaling on cell proliferation, differentiation, and immune system regulation. Mol Endocrinol 16: 1243-1256, 2002